‘It’s a vote for hope’: first gene therapy for muscular dystrophy nears approval, but will it work?
By Sara Reardon,
Nature
| 06. 02. 2023
The road to gene therapies for genetic disorders has been long — and expensive — but the field could soon get some good news. On 22 June, the US Food and Drug Administration will decide whether to grant a fast-track approval to the first gene therapy for Duchenne muscular dystrophy (DMD), a genetic disorder that affects around 1 in 3,500 boys. Children with DMD can’t make a protein called dystrophin, resulting in progressive muscle degeneration and death in their twenties due to heart or respiratory failure.
The therapy, known as SRP-9001, is made by Sarepta Therapeutics based in Cambridge, Massachusetts. It would be the 13th gene therapy that the FDA has approved since 2017, and the first to target a prevalent genetic disease in children. The accelerated approval would allow the drug to reach the market before large clinical trials have been completed, on the basis of evidence that the therapy allows boys to make an engineered form of dystrophin.
The decision date was delayed late in May after FDA officials and advisers raised concerns about the strength of Sarepta’s...
Related Articles
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
By Aaron Ginn, The Washington Post | 09.12.2025
Earlier this year, I had dinner in D.C. with Jensen Huang, the president and chief executive of Nvidia. At one point, he said something that struck me: “Why is everyone here so negative?”
He wasn’t referring to the economy...
By Roni Caryn Rabin, The New York Times | 08.25.2025
Scientists have dreamed for centuries about using animal organs to treat ailing humans. In recent years, those efforts have begun to bear fruit: Researchers have begun transplanting the hearts and kidneys of genetically modified pigs into patients, with varying degrees...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...